143 related articles for article (PubMed ID: 9566814)
1. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach.
Clifford JJ; Waddington JL
Psychopharmacology (Berl); 1998 Apr; 136(3):284-90. PubMed ID: 9566814
[TBL] [Abstract][Full Text] [Related]
2. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
[TBL] [Abstract][Full Text] [Related]
3. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors.
Dall'Olio R; Gaggi R; Voltattorni M; Tanda O; Gandolfi O
Behav Pharmacol; 2002 Dec; 13(8):633-8. PubMed ID: 12478213
[TBL] [Abstract][Full Text] [Related]
4. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.
Gyertyán I; Sághy K
Behav Pharmacol; 2004 Jul; 15(4):253-62. PubMed ID: 15252275
[TBL] [Abstract][Full Text] [Related]
5. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
6. Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models.
Rogóz Z; Kłodzińska A; Maj J
Pol J Pharmacol; 2000; 52(6):459-62. PubMed ID: 11334239
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference.
Gyertyán I; Gál K
Neuroreport; 2003 Jan; 14(1):93-8. PubMed ID: 12544838
[TBL] [Abstract][Full Text] [Related]
8. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine.
Richtand NM; Logue AD; Welge JA; Perdiue J; Tubbs LJ; Spitzer RH; Sethuraman G; Geracioti TD
Brain Res; 2000 Jun; 867(1-2):239-42. PubMed ID: 10837819
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Banasikowski TJ; Beninger RJ
Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
[TBL] [Abstract][Full Text] [Related]
10. Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194a: an analysis of possible mechanisms.
Goudie AJ; Baker LE; Smith JA; Prus AJ; Svensson KA; Cortes-Burgos LA; Wong EH; Haadsma-Svensson S
Behav Pharmacol; 2001 Sep; 12(5):303-15. PubMed ID: 11710745
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a functional role of the dopamine D3 receptors in the cerebellum.
Barik S; de Beaurepaire R
Brain Res; 1996 Oct; 737(1-2):347-50. PubMed ID: 8930390
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat.
Barik S; de Beaurepaire R
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):718-26. PubMed ID: 15913875
[TBL] [Abstract][Full Text] [Related]
13. Effects of the D(3) dopamine receptor antagonist, U99194A, on brain stimulation and d-amphetamine reward, motor activity, and c-fos expression in ad libitum fed and food-restricted rats.
Carr KD; Yamamoto N; Omura M; Cabeza de Vaca S; Krahne L
Psychopharmacology (Berl); 2002 Aug; 163(1):76-84. PubMed ID: 12185403
[TBL] [Abstract][Full Text] [Related]
14. Evidence for dopamine 'D1-like' receptor subtypes in the behavioural effects of two new selective antagonists, LY 270411 and BW 737C.
Deveney AM; Waddington JL
Eur J Pharmacol; 1996 Dec; 317(2-3):175-81. PubMed ID: 8997598
[TBL] [Abstract][Full Text] [Related]
15. D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine.
Chiang YC; Chen PC; Chen JC
Brain Res; 2003 May; 972(1-2):159-67. PubMed ID: 12711089
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice.
Cook CD; Newman JL; Winfree JC; Beardsley PM
Pharmacol Biochem Behav; 2004 Feb; 77(2):309-18. PubMed ID: 14751459
[TBL] [Abstract][Full Text] [Related]
17. Discriminative stimulus properties of the dopamine D3 antagonist PNU-99194A.
Franklin SR; Baker LE; Svensson KA
Psychopharmacology (Berl); 1998 Jul; 138(1):40-6. PubMed ID: 9694525
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour.
Waters N; Löfberg L; Haadsma-Svensson S; Svensson K; Sonesson C; Carlsson A
J Neural Transm Gen Sect; 1994; 98(1):39-55. PubMed ID: 7710738
[TBL] [Abstract][Full Text] [Related]
19. Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine.
Kuballa G; Nowak P; Labus Ł; Bortel A; Dabrowska J; Swoboda M; Kwieciński A; Kostrzewa RM; Brus R
Pharmacol Rep; 2005; 57(2):161-9. PubMed ID: 15886414
[TBL] [Abstract][Full Text] [Related]
20. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.
Millan MJ; Seguin L; Gobert A; Cussac D; Brocco M
Psychopharmacology (Berl); 2004 Jul; 174(3):341-57. PubMed ID: 14985929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
